The Significance of the Ipilimumab/Nivolumab Findings in Melanoma

July 12, 2016
Norman E. Sharpless, MD

Norman E. Sharpless, MD, professor of Medicine and Genetics, chair, the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses the significance of the ipilimumab/nivolumab findings from the CheckMate-069 trial for melanoma.